KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Novavax (NVAX) EBITDA Margin (2016 - 2025)

Novavax has reported EBITDA Margin over the past 16 years, most recently at 9.67% for Q4 2025.

  • Quarterly results put EBITDA Margin at 9.67% for Q4 2025, up 15810.0% from a year ago — trailing twelve months through Dec 2025 was 42.75% (up 7924.0% YoY), and the annual figure for FY2025 was 40.3%, up 7679.0%.
  • EBITDA Margin for Q4 2025 was 9.67% at Novavax, up from 252.7% in the prior quarter.
  • Over the last five years, EBITDA Margin for NVAX hit a ceiling of 77.33% in Q1 2025 and a floor of 386.37% in Q1 2023.
  • Median EBITDA Margin over the past 5 years was 67.71% (2023), compared with a mean of 102.77%.
  • Peak annual rise in EBITDA Margin hit 63138bps in 2021, while the deepest fall reached -508520bps in 2021.
  • Novavax's EBITDA Margin stood at 371.27% in 2021, then skyrocketed by 82bps to 68.24% in 2022, then rose by 8bps to 63.01% in 2023, then plummeted by -136bps to 148.43% in 2024, then skyrocketed by 107bps to 9.67% in 2025.
  • The last three reported values for EBITDA Margin were 9.67% (Q4 2025), 252.7% (Q3 2025), and 57.75% (Q2 2025) per Business Quant data.